Status:

RECRUITING

Impact of Metabolic Health Patterns And Breast Cancer Over Time in Women

Lead Sponsor:

University of Alberta

Collaborating Sponsors:

Canadian Institutes of Health Research (CIHR)

Conditions:

Cardiovascular Diseases

Cardiovascular Morbidity

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

Background \& Rationale: Breast cancer (BC) is the most commonly diagnosed malignancy in women worldwide (2.1 million diagnoses in 2018, 25% of new cancer cases). In Canada, early stage BC mortality ...

Eligibility Criteria

Inclusion

  • Female biological sex at birth
  • \>18 years
  • Diagnosis of stage I, II, or III breast cancer
  • starting neoadjuvant or adjuvant intravenous chemotherapy
  • ECOG \<3;
  • Oncologist approval to participate;
  • English speaking (all study materials and study staff will be in English)
  • Willing and able to adhere to study intervention

Exclusion

  • Individuals who do not have access to a smart phone with Bluetooth capability (required for Fitbit and for responding to intervention text messages) or at least a shared cell phone with someone in the same household (i.e., some couples may share a phone).
  • Type 1 or type 2 diabetes who require exogenous insulin (due to the potential need to adjust insulin dosing with TRE) or with hemoglobin A1c \>10%
  • Research MRI contraindications (e.g., pacemaker, magnetic implants, pregnancy)
  • Uncontrolled thyroid disorder
  • Self-reported eating disorder history
  • Body mass index \<18.5 kg/m2 or clinical signs of cachexia (discretion of treating oncologist)
  • ≥5% body weight loss within last 6 months
  • Those who are currently working night/rotating shifts, eating within ≤10-hour window or consistently eating less than 3 meals/day in the past 3 months.
  • patients who meet the criteria for medical clearance prior to exercise using the Physical Activity Readiness Questionnaire+ and are not cleared by their treating oncologist or family physician to perform maximal exercise testing.

Key Trial Info

Start Date :

March 13 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2027

Estimated Enrollment :

65 Patients enrolled

Trial Details

Trial ID

NCT05432856

Start Date

March 13 2024

End Date

June 1 2027

Last Update

August 27 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

University of Alberta

Edmonton, Alberta, Canada, T6G2R3

2

University of Toronto

Toronto, Ontario, Canada